Cue Biopharma, Inc. CUE
Set alert
20.87 USD -0.58 -2.70%
At close · Oct 30
20.87 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
19.85 Day range 21.16
5.31 52-week range 37.84
- YTD
- +128.09%
- 1 year
- -0.48%
- Open
- 20.66
- Prev close
- 21.45
- Mkt cap
- 151.61M
- Vol
- 60.77K
- Avg vol
- 267.08K
- EPS
- -29.59
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 19.85
- High
- 21.16
- Forward P/E
- -1.79
- Beta
- 1.80
- Short ratio
- 1.54
- Inst. own
- 23.59%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 1.31
- 200-d avg
- 1.26
- 1y target
- 3.60
2Y chart
Events in this range
- Nov 14, 2024Earnings: -0.17; estimate -0.2; surprise 15%
- Apr 24, 2026Split: 1 for 30
Signals (93)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 2 days ago |
| SMA: Bullish | Oct 28, 2026 | 4 days ago |
| MACD: Buy Signal | Oct 28, 2026 | 4 days ago |
| SMA: Bearish | Oct 13, 2026 | 2 weeks ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 28, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| SMA: Bearish | Sep 21, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| SMA: Bullish | Sep 8, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 27, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 18, 2026 | 2 months ago |
| SMA: Bearish | Aug 17, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 13, 2026 | 2 months ago |
| SMA: Bullish | Aug 12, 2026 | 2 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
| SMA: Bullish | Jul 30, 2026 | 3 months ago |
| SMA: Bearish | Jul 29, 2026 | 3 months ago |
| SMA: Bullish | Jul 17, 2026 | 3 months ago |
| SMA: Bearish | Jul 16, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 15, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 30, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 23, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 22, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 12, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 4, 2026 | 5 months ago |
| MACD: Sell Signal | May 14, 2026 | 5 months ago |
| RSI: Overbought | May 5, 2026 | 6 months ago |
| SMA: Bullish | May 1, 2026 | 6 months ago |
| MACD: Buy Signal | May 1, 2026 | 6 months ago |
| SMA: Bearish | Apr 28, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 28, 2026 | 6 months ago |
| SMA: Bullish | Apr 24, 2026 | 6 months ago |
| SMA: Bearish | Apr 23, 2026 | 6 months ago |
| RSI: Overbought | Apr 20, 2026 | 6 months ago |
| SMA: Bullish | Apr 15, 2026 | 6 months ago |
| RSI: Overbought | Apr 15, 2026 | 6 months ago |
| RSI: Overbought | Apr 10, 2026 | 6 months ago |
| SMA: Bullish | Apr 9, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 9, 2026 | 6 months ago |
| RSI: Oversold | Apr 1, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 18, 2026 | 7 months ago |
| SMA: Bearish | Mar 12, 2026 | 7 months ago |
| SMA: Bullish | Mar 11, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 2, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 13, 2026 | 8 months ago |
| MACD: Buy Signal | Jan 2, 2026 | 10 months ago |
| RSI: Oversold | Dec 29, 2025 | 10 months ago |
| RSI: Oversold | Dec 12, 2025 | 10 months ago |
| RSI: Oversold | Dec 9, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 4, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 28, 2025 | 11 months ago |
| RSI: Oversold | Nov 20, 2025 | 11 months ago |
| RSI: Oversold | Nov 17, 2025 | 11 months ago |
| SMA: Bearish | Nov 3, 2025 | 12 months ago |
| SMA: Bullish | Oct 31, 2025 | 1 year ago |
| SMA: Bearish | Oct 27, 2025 | 1 year ago |
| SMA: Bullish | Oct 23, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 23, 2025 | 1 year ago |
| SMA: Bearish | Oct 22, 2025 | 1 year ago |
| SMA: Bearish | Oct 10, 2025 | 1 year ago |
| SMA: Bullish | Oct 9, 2025 | 1 year ago |
| SMA: Bullish | Oct 8, 2025 | 1 year ago |
| RSI: Overbought | Oct 8, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 30, 2025 | 1 year ago |
| RSI: Oversold | Sep 19, 2025 | 1 year ago |
| SMA: Bearish | Aug 29, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 29, 2025 | 1 year ago |
| SMA: Bullish | Jul 7, 2025 | 1 year ago |
| SMA: Bearish | Jun 30, 2025 | 1 year ago |
| SMA: Bullish | Jun 24, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 18, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 17, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 6, 2025 | 1 year ago |
| RSI: Oversold | May 21, 2025 | 1 year ago |
| MACD: Sell Signal | May 20, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 14, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 1, 2025 | 1 year ago |
| RSI: Oversold | Apr 1, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 24, 2025 | 1 year ago |
| SMA: Bearish | Feb 27, 2025 | 1 year ago |
| SMA: Bullish | Feb 26, 2025 | 1 year ago |
| SMA: Bearish | Feb 24, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 20, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 14, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 6, 2025 | 1 year ago |
| SMA: Bullish | Jan 23, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 23, 2025 | 1 year ago |
| SMA: Bearish | Jan 21, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 21, 2025 | 1 year ago |
| SMA: Bullish | Jan 15, 2025 | 1 year ago |
| RSI: Overbought | Jan 6, 2025 | 1 year ago |
Key statistics
- Market cap
- 65.88M
- Enterprise value
- 41.79M
- Trailing P/E
- 0.00
- Forward P/E
- -1.79
- PEG ratio
- 0.00
- Price / sales
- 7.94
- Price / book
- 1.32
- EPS (TTM)
- -0.91
- Beta
- 1.80
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 8.29M
- Revenue growth
- 92.30%
- Free cash flow
- -20.00M
- Total cash
- 30.03M
- Total debt
- 11.26M
- Return on equity
- -138.87%
- Shares outstanding
- 63.35M
- Short % of float
- 2.98%
- 50-day average
- 1.31
- 200-day average
- 1.26
Analyst view
Consensus: none
Price target (mean) 3.60 -82.8% downside
Now 20.87
- Target (low)
- 2.00
- Target (mean)
- 3.60
- Target (high)
- 6.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.145.
Financials — quick view
CUE Revenue — quarterly 7.88M
CUE Net income — quarterly -153.07M
CUE EPS — quarterly -24.14
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.20 | -0.17 | +0.03 | +15.00% |
| Aug 14, 2024 | Jun 1, 2024 | -0.29 | -0.20 | +0.09 | +31.03% |
| Aug 14, 2024 | Jun 1, 2024 | -0.29 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.30 | -0.25 | +0.05 | +16.67% |
| May 9, 2024 | Mar 1, 2024 | -0.30 | — | — | — |
| Apr 8, 2024 | Dec 1, 2023 | 0.00 | -0.28 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 20, 2024 | Stifel | main | Buy | Buy |
| Jul 26, 2024 | JMP Securities | main | Market Outperform | Market Outperform |
| Jul 26, 2024 | Piper Sandler | main | Overweight | Overweight |
| Apr 9, 2024 | Stifel | main | Buy | Buy |
| Apr 9, 2024 | Oppenheimer | main | Outperform | Outperform |
| Apr 3, 2024 | Piper Sandler | reit | Overweight | Overweight |
About Cue Biopharma, Inc.
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cuebiopharma.com
News
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- 12 Health Care Stocks Moving In Friday's Intraday Session
- Cue Biopharma's CUE-221 Hits Phase II Goals, Shows Durable CSU Response
- Cue Biopharma’s CUE-221 Hits Phase II Goals, Shows Durable CSU Response
- Cue Biopharma: Initiating 'Buy' Based On CUE-221 Trial Win CSU With Novel Dual MOA
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous Urticaria Transcript
- What's Going on With Cue Biopharma Stock on Monday?
- What's Going on With Cue Biopharma Stock on Monday?
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
Your note
Sign in to keep a note on CUE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| KIENER PETER A | Director | Sale | Mar 22, 2023 | 357 |
| PASSERI DANIEL R | Chief Executive Officer | Purchase | Dec 15, 2024 | 164,578 |
| SURI ANISH | President | Purchase | Aug 24, 2023 | 135,638 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bleichroeder LP | 7.89% | 4,997,240 | 5.20M | Sep 29, 2024 |
| Slate Path Capital, LP | 3.79% | 2,402,455 | 2.50M | Sep 29, 2024 |
| Vanguard Group Inc | 3.21% | 2,031,421 | 2.11M | Sep 29, 2024 |
| Blackrock Inc. | 0.90% | 570,975 | 593.81K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.80% | 508,827 | 529.18K | Sep 29, 2024 |
| Robertson Stephens Wealth Management, LLC | 0.76% | 478,500 | 497.64K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.13% | 1,347,078 | 1.40M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.94% | 597,569 | 621.47K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.44% | 276,050 | 287.09K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.17% | 110,814 | 115.25K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.14% | 88,916 | 92.47K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.10% | 66,386 | 69.04K | Oct 30, 2024 |